Shots: Baxter to acquire Hillrom for $156.00/ share in cash making a total equity value of ~$10.5B representing a premium of 26% to the stock’s closing price of $124 and […]readmore
Tags : Acquire
Shots: Baxter in talks to acquire Hill-Rom for ~$10B with $150/ share representing a premium of 13% to the stock’s closing price of $132.90. The acquisition is expected to be […]readmore
Shorts: Pfizer will acquire all outstanding shares of Trillium for $18.50/share in cash making a total equity value of $2.26B with 203.8% premium on the stock’s last closing price The […]readmore
Shots: The acquisition will bolster Verily’s clinical trial system and Baseline platform to improve the efficiency, costs in clinical trials & speed up it at research sites globally. It also […]readmore
Shots: Amgen to acquire all outstanding shares of Teneobio for $900M as up front and $1.6B in cash as contingent milestones to Teneobio equity holders. The transaction is expected to […]readmore
Shots: Eli Lilly to acquire Protomer Technologies for ~$1B, with the achievement of future development and commercial milestones Earlier, Lilly led an equity investment in Protomer along with JDRF T1D […]readmore
Shots: Prothena is eligible to receive ~$1.2B as development and commercial milestones including $100M as up front and near-term clinical milestones Novo Nordisk acquires Prothena’s subsidiary and gets WW rights […]readmore
Shots: AbbVie exercised its exclusive right to acquire TeneoOne and its TNB-383B based on an interim analysis of an ongoing P-I study that demonstrated ORR (79%), VGPR (63%), CR (29%) […]readmore
Shots: Tecan to acquire Paramit for ~$1.0B. The transaction is expected to be completed in the coming mos. The acquisition of Paramit will expand Tecan’s footprints solutions for life sciences […]readmore
Shots: Corlieve to receive $55M upfront in cash and is eligible to receive $52.1M as development milestones for P-I/II and $191M for P-III development and the approvals of AMT-260 in […]readmore